Molecular genetic mutation analysis in patients with Fabry disease

2007 ◽  
Vol 91 ◽  
pp. 120-120
Author(s):  
A László ◽  
E Endreffy ◽  
L Török ◽  
JK Ploos Amstel
Diagnostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 415
Author(s):  
Kuntharee Traisrisilp ◽  
Wisit Chankhunaphas ◽  
Rekwan Sittiwangkul ◽  
Chureerat Phokaew ◽  
Vorasuk Shotelersuk ◽  
...  

CHARGE syndrome is a rare autosomal dominant disorder, associated with coloboma (C), heart defects (H), choanal atresia (A), retardation of growth and/or central nervous system (R), genitourinary anomalies (G) and ear abnormalities (E). Prenatal diagnosis of the syndrome is very rare but may be suspected when a combination of such abnormalities is identified. We describe a prenatally suspected case of CHARGE syndrome due to unique findings of cardiac defects (DORV) in combination with minor clues, including a structurally malformed ear with persistent non-response to an acoustic stimulation (which has never been prenatally described elsewhere), renal malrotation and growth restriction. Postnatal diagnosis was made based on confirmation of the prenatal findings and additional specific findings of bilateral coloboma, choanal atresia and ear canal stenosis. Finally, molecular genetic testing by whole exome sequencing of the neonate and her parents revealed a novel de novo heterozygous frameshift c.3506_3509dup variant in the CHD7 gene, confirming the clinical diagnosis of CHARGE syndrome. In conclusion, we describe unique prenatal features of CHARGE syndrome. Educationally, this is one of the rare examples of CHARGE syndrome, comprising all of the six specific anomalies as originally described; it is also supported by the identification of a specific genetic mutation. The identified genetic variant has never been previously reported, thereby expanding the mutational spectrum of CHD7. Finally, this case can inspire prenatal sonographers to increase awareness of subtle or minor abnormalities as genetic sonomarkers.


2006 ◽  
Vol 27 (19) ◽  
pp. 3846-3855 ◽  
Author(s):  
Fuming Sang ◽  
Haixia Ren ◽  
Jicun Ren

Author(s):  
Sang Yee Kim ◽  
Soo Hyun Lee ◽  
Hong Koh ◽  
Seung Tae Lee ◽  
Chang Seok Ki ◽  
...  

Author(s):  
M. A. Kuznetsova ◽  
N. I. Zryachkin ◽  
Yu. A. Tsareva ◽  
E. I. Zueva

Modern ideas about the most severe variant of hereditary tyrosinemia are reflected -- its first type related to orphan diseases (the population frequency of occurrence is 1: 100,000-120,000 live newborns). The latest data on etiology is highlighted (mutations in the gene for the enzyme fumarylacetoacetase (FAA), leading to a deficiency of fumarylacetohydrolase (FAH), the last enzyme in tyrosine catabоlism; the genetic mutation is localized on human chromosome 15q23-q25 and consists of 14 exons) and the mechanisms of development of the disease ( the bypass abnormal pathway of tyrosine metabolism with the formation of highly toxic and carcinogenic metabolites -- succinyl acetoacetate (SAA) and succinylacetone (SA), others; substrate accumulation mainly in FAH-deficient hepatocytes and proximal renal tubule cells; violation of the processes of gluconeogenesis, ammonia detoxification and hepatic protein synthesis), which determine different clinical variants and symptom polymorphism. A modern classification of type I tyrosinemia and a detailed protocol for diagnostic examination of the patient, including instrumental methods, laboratory monitoring of highly toxic derivatives of the tyrosine metabolic pathway and molecular genetic studies, are presented. Denotes a range of diseases that should be carried out a differential diagnosis of tyrosinemia. The modern concept of treatment of this orphan disease (protein-free diet, specialized amino acid mixtures, hepatoprotectors, vitamin D and others) is laid out with an emphasis on enzyme replacement therapy with nitisinone, an enzyme inhibitor (4-hydroxyphenylpyruvate dioxygenase) of the first phase of tyrosine degradation. A description of a clinical case and a 15-year-old teenager with a hereditary tyrosinemia type I who received a low protein diet, the amino acid mixture «XPHEN TYR Tyrosidone» (Nutricia) and nitisinone (Orfadin®).


PLoS ONE ◽  
2014 ◽  
Vol 9 (7) ◽  
pp. e100442 ◽  
Author(s):  
Zhi Xu ◽  
Xinying Huo ◽  
Hua Ye ◽  
Chuanning Tang ◽  
Vijayalakshmi Nandakumar ◽  
...  

2009 ◽  
Vol 75 (10) ◽  
pp. 1116
Author(s):  
Fernando C. Fervenza ◽  
Roser Torra ◽  
Donna J. Lager

Sign in / Sign up

Export Citation Format

Share Document